このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE) (EMERALD)

2026年9月30日 更新者:Biogen

活動性全身性エリテマトーデスの成人参加者におけるBIIB059の継続的な安全性と有効性を評価するための多施設無作為化用量盲検第3相長期延長試験

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on adults who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. This is an extension study of 230LE303 and 230LE304 (TOPAZ-1 and TOPAZ-2). It will include participants who completed the treatment periods of either one of those parent studies.

The main goal of the study is to learn more about the long-term safety of litifilimab in adults. The main question researchers want to answer is:

- How many participants have adverse events and serious adverse events during the study? Adverse events are health problems that may or may not be caused by the study drug.

Researchers will also learn about:

  • The effect of litifilimab on controlling symptoms of SLE and lowering its activity.
  • How participants' immune systems respond to litifilimab.
  • The effect of litifilimab on the quality of life of participants.

The study will be done as follows:

  • This study begins when the participant has finished 1 of the parent studies (either 230LE303 or 230LE304).
  • Participants who were getting either a high or low dose of litifilimab in either parent study will continue getting the same doses.
  • Participants who were getting the placebo in the parent studies will be randomized to get either a high or low dose of litifilimab.
  • Neither the researchers nor the participants will know which doses of litifilimab the participants are getting.
  • All participants will get litifilimab as injections under the skin once every 4 weeks. The treatment period will last up to 260 weeks. Participants may continue to take their standard of care medications.
  • There will be a follow-up safety period that lasts up to 24 weeks.
  • In total, participants will have up to 73 study visits. At these visits, the study doctor will do tests to check the participants' overall health, including the status of their SLE symptoms. They will also measure the participants' height, weight, and vital signs and collect blood and urine samples. Participants will also complete questionnaires or answer questions about how they are feeling and about their daily lives.
  • Each participant will be in the study for up to 284 weeks.

Optional Substudy:

  • Some participants may be invited to join an optional "substudy" after being in the main study for at least 4 months.
  • This substudy will test a new injector device for delivering litifilimab. The injector device is an automatic device that delivers the full dose in 1 injection without needing to push a plunger.
  • Researchers will learn more about the safety of the injector device and how the body reacts to it. This will be compared to the current prefilled syringe method.
  • The substudy will last up to 3 months and will include about 120 participants.

調査の概要

詳細な説明

This is an extension study for all participants who completed study 230LE303 (NCT04895241) and 230LE304 (NCT04961567) (parent phase 3 studies) through Week 52 and did not discontinue litifilimab or placebo. Eligible participants from parent phase 3 studies will be followed for up to 284 weeks.

The primary objective of this study is to evaluate the long-term safety and tolerability of litifilimab in participants with active systemic lupus erythematosus (SLE).

The secondary objectives of this study are to evaluate the long-term effect of litifilimab on disease activity in participants with SLE, to evaluate the long-term effect of litifilimab in participants with SLE in maintaining low disease activity, to evaluate the effect of litifilimab in participants with active SLE in preventing irreversible organ damage, to assess long-term use of oral corticosteroid (OCS) with participants receiving litifilimab treatment, to assess the impact of litifilimab on participant-reported Health-Related Quality-of-Life Questionnaire (HRQoL), symptoms, and impacts of SLE, to evaluate long-term effect of litifilimab on laboratory parameters, and to evaluate immunogenicity of litifilimab.

A phase-3, randomized, dose-blind, substudy is added in this extension study for all participants who have been enrolled in the 230LE306 Phase 3 LTE study for a minimum of 4 months and have at least four remaining visits in the Phase 3 LTE study.

The primary objective of this substudy is to evaluate the safety of injector device used for administering litifilimab in participants with active SLE.

The secondary objective of this substudy is to evaluate the tolerability of injector device used for administering litifilimab in participants with active SLE.

研究の種類

介入

入学 (推定)

864

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Arizona
      • Phoenix、Arizona、アメリカ、85037
        • Arizona Arthritis & Rheumatology Associates, P.C.
    • California
      • Beverly Hills、California、アメリカ、90211
        • Wallace Rheumatic Study Center
      • Huntington Beach、California、アメリカ、92648
        • Care Access Research - Huntington Beach
      • Mission Hills、California、アメリカ、91345
        • Providence Facey Medical Foundation
      • Upland、California、アメリカ、91786
        • Inland Rheumatology Clinical Trials, Inc.
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • University of Colorado Denver
    • District of Columbia
      • Washington D.C.、District of Columbia、アメリカ、20007-2113
        • Georgetown University Hospital-Medstar
    • Florida
      • Aventura、Florida、アメリカ、33180
        • Arthritis & Rheumatic Disease Specialties
      • Avon Park、Florida、アメリカ、33825
        • Highlands Research Institute
      • Clearwater、Florida、アメリカ、33765
        • Clinical Research of West Florida - Corporate
      • Cooper City、Florida、アメリカ、33024
        • GNP Research at Mark Jaffe, MD
      • DeBary、Florida、アメリカ、32713
        • Omega Research Consultants
      • Margate、Florida、アメリカ、33063
        • Life Clinical Trials
      • Orlando、Florida、アメリカ、32819
        • HMD Research, LLC
      • Tampa、Florida、アメリカ、33606
        • Clinical Research of West Florida, Inc.
      • Tampa、Florida、アメリカ、33613
        • AdventHealth Medical Group
    • Georgia
      • Gainesville、Georgia、アメリカ、30501
        • Arthritis Center of North Georgia
    • Massachusetts
      • Worcester、Massachusetts、アメリカ、01655
        • University of Massachusetts Chan Medical School
    • Michigan
      • Flint、Michigan、アメリカ、48504
        • AA MRC LLC Ahmed Arif Medical Research Center
      • Rochester Hills、Michigan、アメリカ、48307
        • Precision Comprehensive Clinical Research Solutions
    • Missouri
      • St Louis、Missouri、アメリカ、63119
        • Saint Louis Rheumatology
    • New York
      • Brooklyn、New York、アメリカ、11220
        • NYU Langone Brooklyn
    • North Carolina
      • Charlotte、North Carolina、アメリカ、28210
        • DJL Clinical Research, PLLC
      • Salisbury、North Carolina、アメリカ、28144
        • Onyx Clinical Research, LLC
    • Ohio
      • Cincinnati、Ohio、アメリカ、45219
        • University of Cincinnati
      • Middleburg Heights、Ohio、アメリカ、44130
        • Paramount Medical Research & Consulting, LLC
    • Tennessee
      • Jackson、Tennessee、アメリカ、38305
        • West Tennessee Research Institute
      • Memphis、Tennessee、アメリカ、38119
        • Ramesh C Gupta, MD
    • Texas
      • Allen、Texas、アメリカ、75013
        • Arthritis & Rheumatology Research Institute
      • Austin、Texas、アメリカ、78745
        • Tekton Research - PARENT
      • Baytown、Texas、アメリカ、77521
        • Accurate Clinical Research
      • Colleyville、Texas、アメリカ、76034-5913
        • Precision Comprehensive Clinical Research Solution
      • Houston、Texas、アメリカ、77054
        • Prolato Clinical Research Center
      • Humble、Texas、アメリカ、77338
        • Accurate Clinical Research, Inc.
      • Katy、Texas、アメリカ、77450
        • R and H Clinical Research
      • San Antonio、Texas、アメリカ、78215
        • Sun Research Institute, LLC
      • The Woodlands、Texas、アメリカ、77382
        • Advanced Rheumatology of Houston
    • Washington
      • Seattle、Washington、アメリカ、98104
        • Swedish Medical Center
      • Buenos Aires、アルゼンチン、17251900
        • Hospital Italiano de La Plata
      • Buenos Aires、アルゼンチン、3151878
        • Instituto de Investigaciones Clinicas Quilmes
      • Buenos Aires、アルゼンチン、7600
        • Cenemar SRL
      • Ciudad Autonoma Buenos Aires、アルゼンチン、1425
        • Centro Medico Dra Laura Maffei Investigacion Clinica Aplicada
      • Ciudad Autonoma Buenos Aires、アルゼンチン、C1013AAB
        • STAT Research S.A.
      • Córdoba、アルゼンチン、5000
        • Sanatorio Allende
      • Mendoza、アルゼンチン、5500
        • Instituto de Reumatologia
      • San Juan、アルゼンチン、5400
        • CER San Juan Centro Polivalente de Asistencia e Inv. Clinica
    • Buenos Aires
      • CABA、Buenos Aires、アルゼンチン、C1015ABO
        • Organizacion Medica de Investigacion (OMI)
      • Mar del Plata、Buenos Aires、アルゼンチン、7600
        • Centro de Investigaciones Medicas Mar del Plata
      • Mar del Plata、Buenos Aires、アルゼンチン、B7600GNY
        • Policlìnica Red Omip S.A - Ensayos Clinicos GC
      • San Miguel、Buenos Aires、アルゼンチン、B1663
        • Centro Dermatologico Schejtman
    • Ciudad Autonoma Buenos Aires
      • Buenos Aires、Ciudad Autonoma Buenos Aires、アルゼンチン、1425
        • Centro Medico Barrio Parque
      • Buenos Aires、Ciudad Autonoma Buenos Aires、アルゼンチン、1406
        • APRILLUS Asistencia e Investigacion
    • Mendoza Province
      • Villa Nueva、Mendoza Province、アルゼンチン、CP 5519
        • Consultorio Alto Dorrego
    • Santa Fe Province
      • Rosario、Santa Fe Province、アルゼンチン、S2000PBJ
        • Instituto CAICI
    • Tucumán Province
      • San Miguel de Tucumán、Tucumán Province、アルゼンチン、T4000ICL
        • Investigaciones Clinicas Tucuman
      • San Miguel de Tucumán、Tucumán Province、アルゼンチン、4000
        • Clinica Mayo de Urgencias Medicas Cruz Blanca SRL
      • San Miguel de Tucumán、Tucumán Province、アルゼンチン、T4000AXL
        • Centro de Investigaciones Medicas Tucuman
    • Greater London
      • London、Greater London、イギリス、SE1 9RT
        • Guy's Hospital
    • South Yorkshire
      • Doncaster、South Yorkshire、イギリス、DN2 5LT
        • Doncaster Royal Infirmary
    • Staffordshire
      • Cannock、Staffordshire、イギリス、WS11 5XY
        • Cannock Chase Hospital
      • Haifa、イスラエル、3109601
        • Rambam Health Care Campus
      • Kfar Saba、イスラエル、44281
        • Meir Medical Center
      • Ramat Gan、イスラエル、5265601
        • Chaim Sheba Medical Center
      • Tel Aviv、イスラエル、6423906
        • Tel Aviv Sourasky Medical Center Pt
      • Roma、イタリア、152
        • Azienda Ospedaliera San Camillo Forlanini
      • Cherkasy、ウクライナ、18009
        • CNE Cherkasy Regional Hospital of Cherkasy Regional Council,
      • Ivano-Frankivsk、ウクライナ、76018
        • CNE Regional Clinical Hospital of IFRC, Center of Cardiology, Rheumatology & Interventional Med.;
      • Kyiv、ウクライナ、02125
        • CNE Kyiv City Clinical Hospital #3
      • Poltava、ウクライナ、36011
        • CE M.V. Sklifosovskyi Poltava Regional Clinical Hospital of PRC
      • Vinnytsia、ウクライナ、21018
        • University Clinic of NPMMU, Vinnytsya (TESC). Dep of Rheumatology with therapeutic beds,
      • Vinnytsia、ウクライナ、21001
        • Private Small Enterprise, Medical Centre 'Pulse'
      • Vinnytsia、ウクライナ、21008
        • CNE M.I. Pyrohov Vinnytsia Reg Clinic Hosp, HSC Center of Rheumatol, Osteoporosis & Biologic Therapy
    • Ontario
      • Toronto、Ontario、カナダ、M5T 2S8
        • Toronto Western Hospital
    • Attica
      • Athens、Attica、ギリシャ、11521
        • NNA Hospital
      • Armenia、コロンビア、630004
        • Fundacion Cardiomet CEQUIN S.A.S
      • Barranquilla、コロンビア、080020
        • Centro de Investigacion Medico Asistencial S.A.S
      • Barranquilla、コロンビア、080020
        • Clínica de la Costa S.A.S
      • Bogotá、コロンビア、110221
        • Centro de Investigacion en Reumatologia y Especialidades Medicas CIREEM S.A.S.
      • Bucaramanga、コロンビア、680003
        • Servimed S.A.S.
      • Chía、コロンビア、250001
        • Preventive Care Ltda
      • Floridablanca、コロンビア、681004
        • Fundacion Oftalmologica de Santander - FOSCAL
      • Manizales、コロンビア、170004
        • IPS Medicos Internistas de Caldas S.A.S.
      • Medellín、コロンビア、050021
        • Centro de Investigacion Clinica CIC
      • Zipaquirá、コロンビア、250252
        • Healthy Medical Center
    • Valle del Cauca Department
      • Cali、Valle del Cauca Department、コロンビア、760001
        • IPS Centro Medico Julian Coronel S.A.
      • Barcelona、スペイン、08035
        • Hospital Universitari Vall d'Hebron
      • Seville、スペイン、41010
        • Hospital Quironsalud Infanta Luisa
    • Castellón
      • Castellon、Castellón、スペイン、12004
        • Hospital General de Castellon
      • Santander、Castellón、スペイン、39008
        • Hospital Universitario Marques de Valdecilla
    • Sevilla
      • Seville、Sevilla、スペイン、41009
        • Hospital Universitario Virgen Macarena
      • Belgrade、セルビア、11000
        • Institute of Rheumatology
      • Belgrade、セルビア、11000
        • University Clinical Center of Serbia
      • Belgrade、セルビア、11080
        • Clinical Center "Bezanijska Kosa "
      • Brno、チェコ、63800
        • Revmatologie s.r.o.
      • Olomouc、チェコ、77520
        • Fakultni nemocnice Olomouc
      • Santiago、チリ、7500710
        • BioMedica Research Group
      • Santiago、チリ、7500000
        • Centro Medico Prosalud
      • Santiago、チリ、7500571
        • CTR Estudios
      • Santiago、チリ、7500587
        • Enroll Spa
      • Valdivia、チリ、5090000
        • Clinical Research Chile SpA.
      • Budapest、ハンガリー、1097
        • Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
      • Gyula、ハンガリー、5700
        • Bekes Varmegyei Kozponti Korhaz
      • Veszprém、ハンガリー、8200
        • Vital Medical Center
    • Fejér
      • Székesfehérvár、Fejér、ハンガリー、8000
        • Vita Verum Medical Egeszsegugyi Szolgaltato Bt.
      • City of Taguig、フィリピン、1642
        • Ospital Ng Makati
      • Iloilo City、フィリピン、5000
        • The Medical City Iloilo
      • Mabalacat, Pampanga、フィリピン、2023
        • The Medical City Clark
      • Manila、フィリピン、1000
        • Medical Center Manila
      • Manila、フィリピン、1012
        • Jose R. Reyes Memorial Medical Center
      • San Fernando City, La Union、フィリピン、2500
        • Lorma Medical Center
    • Batangas
      • Lipa City、Batangas、フィリピン、4217
        • Mary Mediatrix Medical Center
    • Davao Region
      • Davao City、Davao Region、フィリピン、8000
        • Davao Doctors Hospital
    • National Capital Region
      • Manila、National Capital Region、フィリピン、1000
        • University of the Philippines Manila - Philippine General Hospital
      • Quezon City、National Capital Region、フィリピン、1102
        • St. Luke's Medical Center
      • Quezon City、National Capital Region、フィリピン、1118
        • Far Eastern University - Dr. Nicanor Reyes Medical Foundation
    • Drôme
      • Clermont-Ferrand、Drôme、フランス、63003
        • CHU Clermont Ferrand - Hopital Gabriel Montpied
      • São Paulo、ブラジル、04037-030
        • RDSS Ricardo Diaz Scientific Solution
      • São Paulo、ブラジル、01228-200
        • CPCLIN - Centro de Pesquisas Clinicas
    • Ceará
      • Fortaleza、Ceará、ブラジル、60430-372
        • HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará
    • Espírito Santo
      • Vitória、Espírito Santo、ブラジル、29055-450
        • CEDOES - Diagnóstico e Pesquisa
    • Estado de Bahia
      • Salvador、Estado de Bahia、ブラジル、40150-150
        • Clínica SER da Bahia
    • Federal District
      • Brasília、Federal District、ブラジル、70200-730
        • L2IP - Instituto de Pesquisas Clínicas Ltda.
    • Mato Grosso
      • Santo Ângelo、Mato Grosso、ブラジル、78020-500
        • IPC MT Instituto de Pesquisas Clinicas do Mato Grosso
    • Minas Gerais
      • Belo Horizonte、Minas Gerais、ブラジル、30150-221
        • Santa Casa de Misericordia de Belo Horizonte
      • Juiz de Fora、Minas Gerais、ブラジル、36010-570
        • CMiP - Centro Mineiro de Pesquisa
    • Paraná
      • Curitiba、Paraná、ブラジル、80030-110
        • CETI - Centro de Estudos em Terapias Inovadoras Ltda.
    • Rio Grande do Sul
      • Porto Alegre、Rio Grande do Sul、ブラジル、90480-000
        • LMK Serviços Médicos S/S Ltda
      • Porto Alegre、Rio Grande do Sul、ブラジル、90560032
        • Hospital Moinhos de Vento
      • Porto Alegre、Rio Grande do Sul、ブラジル、90035-903
        • Hospital de Clínicas de Porto Alegre
    • São Paulo
      • Sao Jose Rio Preto、São Paulo、ブラジル、15090-000
        • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
      • São Bernardo do Campo、São Paulo、ブラジル、09715-090
        • Centro Multidisciplinar de Estudos Clínicos - CEMEC
      • São Paulo、São Paulo、ブラジル、01228-200
        • CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos
      • Valinhos、São Paulo、ブラジル、13271-130
        • A2Z Clinical Centro Avancado de Pesquisa Clinica
      • Plovdiv、ブルガリア、4003
        • UMHAT-Plovdiv AD
      • Plovdiv、ブルガリア、4002
        • MC Artmed OOD
      • Plovdiv、ブルガリア、4002
        • UMHAT "Pulmed" OOD
      • Rousse、ブルガリア、7002
        • DCC 1 - Ruse, EOOD
      • Sofia、ブルガリア、1431
        • DCC 'Alexandrovska', EOOD
      • Sofia、ブルガリア、1606
        • Military Medical Academy - MHAT - Sofia
      • Sofia、ブルガリア、1463
        • DCC Focus 5 - MEOH OOD
      • Sofia、ブルガリア、1612
        • UMHAT 'Sv. Ivan Rilski', EAD
      • Caguas、プエルトリコ、00725
        • Centro Reumatologico
      • Liège、ベルギー、4000
        • Centre Hospitalier Universitaire de Liege
      • Lima、ペルー、LIMA 29
        • HMA - Hospital Maria Auxiliadora
      • Lima、ペルー、LIMA 11
        • Centro de Investigacion Clinica Inmunoreumatologia - ACQ Medic
      • Lima、ペルー、LIMA 33
        • Invest Clinicas Sac Inst de Ginecologia y Reproduccion
      • Bialystok、ポーランド、15-707
        • Nova Reuma Domysławska i Rusiłowicz, Spółka Partnerska Lekarza Reumatologa i Fizjoterapeuty
      • Bydgoszcz、ポーランド、87-100
        • Szpital Uniwersytecki nr 2 im.dr J. Biziela
      • Bytom、ポーランド、41-902
        • Nzoz Bif-Med
      • Krakow、ポーランド、30-510
        • Pratia MCM Krakow
      • Malbork、ポーランド、82-200
        • Centrum Badawcze Panaceum Agnieszka Brzezicka, Magdalena Lenkiewicz Sp. z o.o.
      • Poznan、ポーランド、61-441
        • Gabinety Lekarskie Rivermed
      • Poznan、ポーランド、61-397
        • Prywatna Praktyka Lekarska prof Pawel Hrycaj
      • Warsaw、ポーランド、00-874
        • MICS Centrum Medyczne Warszawa
      • Warsaw、ポーランド、00-719
        • Przychodnia Care Access Warszawa
      • Chihuahua City、メキシコ、31000
        • Investigacion y Biomedicina de Chihuahua, S.C.
      • Durango、メキシコ、34080
        • Centro de Investigacion y Atencion Integral Durango CIAID
    • Jalisco
      • Guadalajara、Jalisco、メキシコ、44650
        • Clinica de Investigacion en Reumatologia y Obesidad S.C.
      • Guadalajara、Jalisco、メキシコ、44950
        • Centro de investigacion medica y reumatologia
    • Mexico City
      • Mexico City、Mexico City、メキシコ、06700
        • Clinstile, S.A. de C.V.
      • Mexico City、Mexico City、メキシコ、03720
        • Centro de Investigacion Clínica GRAMEL S.C
      • Mexico City、Mexico City、メキシコ、14080
        • Instituto Nacional de Ciencias Medicas y Nutricion Dr. Salvador Zubiran
    • Morelos
      • Cuernavaca、Morelos、メキシコ、62448
        • Consultorio Privado Dr. Miguel Cortes Hernandez
    • Nuevo León
      • Monterrey、Nuevo León、メキシコ、64000
        • Accelerium S. de R.L. de C.V.
    • Yucatán
      • Mérida、Yucatán、メキシコ、97000
        • Centro Peninsular de Investigacion Clinica, SCP
      • Mérida、Yucatán、メキシコ、97070
        • Medical Care & Research SA de CV
      • Brasov、ルーマニア、500283
        • S.C Centrul Medical de Diagnostic si Tratament Ambulator Neomed S.R.L
      • Bucharest、ルーマニア、14142
        • S C Delta Health Care SRL
      • Bucharest、ルーマニア、041303
        • HIPERDIA SA- Centrul de Diagnostic si Tratament Hiperdia Oltenitei
      • Cluj-Napoca、ルーマニア、400006
        • Spitalul Clinic Judetean de Urgenta Cluj Napoca
      • Iași、ルーマニア、700023
        • S.C.Centrul Medical Unirea SRL
      • Changchun、中国、130021
        • The First Hospital of Jilin University
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100053
        • Xuanwu Hospital Capital Medical University
    • Guangdong
      • Dongguan、Guangdong、中国、523059
        • Dongguan People's Hospital
      • Guangzhou、Guangdong、中国、510317
        • Guangdong Second Provincial General Hospital
      • Guangzhou、Guangdong、中国、510515
        • Nanfang Hospital of Southern Medical University
      • Shenzhen、Guangdong、中国、518020
        • Shenzhen People's Hospital
      • Zhongshan、Guangdong、中国、528400
        • Zhongshan TCM Hospital
    • Hainan
      • Haikou、Hainan、中国、570311
        • Hainan General Hospital
    • Hebei
      • Shijiazhuang、Hebei、中国、50000
        • The Second Hospital of Hebei Medical University
    • Hu'nan
      • Changsha、Hu'nan、中国、410008
        • Xiangya Hospital, Central South University
      • Zhuzhou、Hu'nan、中国、412000
        • ZhuZhou Central Hospital
    • Jiangsushe
      • Suzhou、Jiangsushe、中国、215004
        • The Second Affiliated Hospital of Soochow University
    • Jiangxi
      • Jiujiang、Jiangxi、中国、332000
        • Jiujiang No.1 People's Hospital
      • Pingxiang、Jiangxi、中国、337055
        • Pingxiang People's Hospital
    • Jilin
      • Changchun、Jilin、中国、130021
        • Jilin Province People's Hospital
    • Shandong
      • Binzhou、Shandong、中国、256603
        • Binzhou Medical University Hospital
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200001
        • Renji Hospital Shanghai Jiaotong University School of Medicine - West Branch
    • Zhejiang
      • Ningbo、Zhejiang、中国、315010
        • The First Affiliated Hospital of Ningbo University
      • Kaohsiung City、台湾、833401
        • Kaohsiung Chang Gung Memorial Hospital
      • Taichung、台湾、40201
        • Chung Shan Medical University Hospital
    • Aichi-ken
      • Nagoya、Aichi-ken、日本、457-8510
        • JCHO Chukyo Hospital
      • Toyoake-shi、Aichi-ken、日本、470-1192
        • Fujita Health University Hospital
    • Chiba
      • Chiba、Chiba、日本、260-8712
        • NHO Chibahigashi National Hospital
    • Fukuoka
      • Fukuoka、Fukuoka、日本、810-8539
        • KKR Hamanomachi Hospital
      • Fukuoka、Fukuoka、日本、810-8563
        • NHO Kyushu Medical Center
      • Kitakyushu-shi、Fukuoka、日本、807-8556
        • Hospital of the University of Occupational and Environmental Health
    • Hiroshima
      • Hiroshima、Hiroshima、日本、734-8551
        • Hiroshima University Hospital
    • Hokkaido
      • Sapporo、Hokkaido、日本、060-0004
        • Tonan Hospital
    • Hyōgo
      • Himeji-shi、Hyōgo、日本、670-8540
        • Japanese Red Cross Society Himeji Hospital
      • Kobe、Hyōgo、日本、650-0017
        • Kobe University Hospital
      • Kobe、Hyōgo、日本、650-0047
        • Kobe City Hospital Organization Kobe City Medical Center General Hospital
    • Kagawa-ken
      • Kita-gun、Kagawa-ken、日本、761-0793
        • Kagawa University Hospital
    • Kagoshima-ken
      • Kagoshima、Kagoshima-ken、日本、890-0063
        • Eiraku Clinic
    • Kanagawa
      • Yokohama、Kanagawa、日本、232-0024
        • Yokohama City University Medical Center
      • Yokohama、Kanagawa、日本、245-8575
        • NHO Yokohama Medical Center
    • Kumamoto
      • Kumamoto、Kumamoto、日本、861-8520
        • Japanese Red Cross Kumamoto Hospital
    • Osaka
      • Kawachinagano-shi、Osaka、日本、586-8521
        • NHO Osaka Minami Medical Center
      • Osakasayama-shi、Osaka、日本、589-8511
        • Kindai University Hospital
    • Tokyo-To
      • Meguro-ku、Tokyo-To、日本、153-8515
        • Toho University Ohashi Medical Center
      • Shinjuku-ku、Tokyo-To、日本、162-8655
        • Center Hospital of the National Center for Global Health and Medicine
      • tabashi City、Tokyo-To、日本、173-8610
        • Nihon University Itabashi Hospital
      • Seoul、韓国、4763
        • Hanyang University Seoul Hospital
    • Gyeonggi-do
      • Suwon、Gyeonggi-do、韓国、16499
        • Ajou University Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Key Inclusion Criteria:

  • Participants who completed 1 of the 52-week of the double-blind placebo-controlled, parent Phase 3 studies (230LE303 (NCT04895241) and 230LE304 (NCT04961567)) on study treatments with either litifilimab or placebo to Week 48 and attended the last study assessment visit at Week 52.

Key Exclusion Criteria:

  • Early parent Phase 3 studies treatment terminators (participants who discontinued study treatment before Week 52)
  • Early parent Phase 3 studies terminators (participants who withdrew from study participation and did not complete the 52-week treatment period)
  • Participants who developed moderate-to-severe worsening of organ-specific lupus manifestations that would require a change in antimalarials and/or immunosuppressive therapy (initiation of new treatment or increase in dose above the allowed maximum dose)
  • Use of other investigational drugs or off-label drugs used to treat SLE, cutaneous lupus, or lupus nephritis during the parent Phase 3 studies.

NOTE: Other inclusion/exclusion criteria may apply.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Litifilimab Low Dose

Participants who are receiving background nonbiologic lupus standard of care (SOC) therapy and received litifilimab low dose, subcutaneously (SC), every 4 weeks (Q4W) during the parent Phase 3 studies (i.e. studies 230LE303 [NCT04895241] or 230LE304 [NCT04961567]) will continue to receive litifilimab low dose, SC, Q4W from Day 1 to 260 weeks with an additional dose of litifilimab-matching placebo at Week 2.

Participants who are receiving background nonbiologic lupus SOC therapy and received litifilimab-matching placebo in the parent Phase 3 studies (i.e. studies 230LE303 [NCT04895241] or 230LE304 [NCT04961567]) will be randomized to receive litifilimab low dose, SC, Q4W from Day 1 to 260 weeks with an additional dose at Week 2.

Administered as specified in the treatment arm.

他の名前:
  • BIIB059

Administered as specified in the treatment arm.

他の名前:
  • BIIB059
実験的:Litifilimab High Dose

Participants who are receiving background nonbiologic lupus SOC therapy and received litifilimab high dose, SC, Q4W during the parent Phase 3 studies (i.e. studies 230LE303 [NCT04895241] or 230LE304 [NCT04961567]) will continue to receive litifilimab high dose, SC, Q4W from Day 1 to 260 weeks with an additional dose of litifilimab-matching placebo at Week 2.

Participants who are receiving background nonbiologic lupus SOC therapy and received litifilimab-matching placebo in the parent Phase 3 studies (i.e. studies 230LE303 [NCT04895241] or 230LE304 [NCT04961567]) will be randomized to receive litifilimab high dose, SC, Q4W from Day 1 to 260 weeks with an additional dose at Week 2.

Administered as specified in the treatment arm.

他の名前:
  • BIIB059

Administered as specified in the treatment arm.

他の名前:
  • BIIB059

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants with Treatment Emergent Adverse Events (TEAEs)
時間枠:Up to Week 284

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is an AE that started or worsened in severity after the first dose of study treatment through 28 days after the last dose of study treatment or end of study (EOS) date, whichever comes earlier.

Up to Week 284
Number of Participants with Serious Adverse Events (SAEs)
時間枠:Up to Week 284

An SAE is any untoward medical occurrence that at any dose results in death, in the view of the Investigator, places the participant at immediate risk of death (a life threatening event), requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, and is a medically important event.

Up to Week 284

二次結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants who Achieved an Systemic Lupus Erythematosus Responder Index (SRI)-4 Response
時間枠:Up to Week 284

SRI-4 is a composite endpoint defined as the following:

  • A reduction from baseline of ≥4 points in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) score.
  • No new organ system affected, as defined by no new British Isles Lupus Activity Group-2004 (BILAG-2004 grade A) and no more than 1 new BILAG 2004 grade B versus previous visit.
  • No worsening from baseline in lupus disease activity as defined by <0.3-point increase on 3-point Physician's Global Assessment (PGA) visual analog scale (VAS).
  • No violation of protocol-specified medication rules
Up to Week 284
Percentage of Participants With at Least 4 Joints (Both Swollen and Tender) at Baseline who Achieved a Joint-50 Response
時間枠:Up to Week 284

Joint-50 response is a 50% reduction in total active joint count from baseline. An active joint is defined as a joint with pain and signs of inflammation (e.g., tenderness, swelling or effusion). A 28-joint assessment will be performed to determine the active joint count, which is defined as the sum of tender and swollen joint counts.

Up to Week 284
Percentage of Participants With a Cutaneous Lupus Erythematosus Disease Area and Severity Index - Activity (CLASI-A) Score ≥10 at Baseline who Achieved a CLASI-50, CLASI-70, and CLASI-90 Response
時間枠:Up to Week 284

CLASI score is used to evaluate lupus skin manifestations. The activity scale (CLASI-A) includes measurements of erythema, scale and hypertrophy, and mucous membrane disease. Each part of the body is listed separately, from the scalp to the feet, in addition to sections focusing on mucous membrane involvement and alopecia. Points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. Scores for each area are assigned based on the most severe lesion within the area of interest. CLASI-A scores of 0 to 9, 10 to 20, and 21 to 70 represent disease severity of mild, moderate, and severe, respectively. CLASI-50, CLASI-70, and CLASI-90 responders are defined as ≥ 50%, ≥ 70%, and ≥ 90% improvement in CLASI-A score from baseline at the specified timepoint.

Up to Week 284
Percentage of Participants who Achieved a British Isles Lupus Assessment Group based Composite Lupus Assessment (BICLA) Response
時間枠:Up to Week 260

BICLA is a composite endpoint defined as the following:

  • BILAG-2004 improvement, defined as all of BILAG-2004 Grade A at baseline improved to B, C, or D and all of BILAG-2004 Grade B at baseline improved to C or D.
  • No BILAG-2004 worsening in other BILAG-2004 organ systems such that there are no new BILAG-2004 Grade A or greater than 1 new BILAG-2004 Grade B.
  • No worsening in the SLEDAI-2K total score compared to baseline.
  • No worsening from baseline in lupus disease activity as defined by <0.3-point increase on 3-point PGA VAS.
  • No violation of protocol-specified medication rules.
Up to Week 260
Annualized Severe Safety of Estrogens in Systemic Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index Flare Index (SFI) Flare Rate
時間枠:Up to Week 260

A severe flare is defined as any of the following:

  • Change in SLEDAI instrument score to >12
  • New or worse: central nervous system SLE; vasculitis; nephritis; myositis; platelets <60,000/mL, or hemolytic anemia with hemoglobin <7 grams per deciliter (g/dL) or decrease in hemoglobin >3 g/dL and requiring: doubling prednisone dose, increase to >0.5 milligrams per kilograms per day (mg/kg/day) or hospitalization
  • Increase in prednisone dose to >0.5 mg/kg/day
  • New requirement for cyclophosphamide, azathioprine, methotrexate, or mycophenolate for SLE activity
  • Hospitalization for SLE activity
  • Increase in PGA score to >2.5
Up to Week 260
Percentage of Time Spent in Lupus Low Disease Activity State (LLDAS)
時間枠:Up to Week 284

LLDAS is a composite endpoint defined as the following:

i. SLEDAI-2K score ≤ 4, with no activity in a major organ system (renal, central nervous system, cardiopulmonary, vasculitis, fever); and ii. No new features of lupus disease activity compared with the previous assessment; and iii. SELENA-SLEDAI PGA ≤ 1; and iv. Current prednisone (or equivalent) dose ≤ 7.5 mg/day; and v. Standard maintenance doses of immunosuppressive drugs and approved biological agents.

"No new features" is defined as any new SLEDAI-2K component that was not present at the previous assessment. The SELENA-SLEDAI PGA Scale ranges from 0-3, where 0 is no disease activity and 3 is maximum disease activity. "Standard maintenance doses" include drugs limited to those allowed per protocol.

Up to Week 284
Percentage of Participants With Sustained LLDAS
時間枠:Up to Week 284

LLDAS is a composite endpoint defined as the following:

i. SLEDAI-2K score ≤ 4, with no activity in a major organ system (renal, central nervous system, cardiopulmonary, vasculitis, fever); and ii. No new features of lupus disease activity compared with the previous assessment; and iii. SELENA-SLEDAI PGA ≤ 1; and iv. Current prednisone (or equivalent) dose ≤ 7.5 mg/day; and v. Standard maintenance doses of immunosuppressive drugs and approved biological agents.

"No new features" is defined as any new SLEDAI-2K component that was not present at the previous assessment. The SELENA-SLEDAI PGA Scale ranges from 0-3, where 0 is no disease activity and 3 is maximum disease activity. "Standard maintenance doses" include drugs limited to those allowed per protocol.

Up to Week 284
Duration of Sustained LLDAS as Defined by the Number of Visits in LLDAS
時間枠:Up to Week 284

LLDAS is a composite endpoint defined as the following:

i. SLEDAI-2K score ≤ 4, with no activity in a major organ system (renal, central nervous system, cardiopulmonary, vasculitis, fever); and ii. No new features of lupus disease activity compared with the previous assessment; and iii. SELENA-SLEDAI PGA ≤ 1; and iv. Current prednisone (or equivalent) dose ≤ 7.5 mg/day; and v. Standard maintenance doses of immunosuppressive drugs and approved biological agents.

"No new features" is defined as any new SLEDAI-2K component that was not present at the previous assessment. The SELENA-SLEDAI PGA Scale ranges from 0-3, where 0 is no disease activity and 3 is maximum disease activity. "Standard maintenance doses" include drugs limited to those allowed per protocol.

Up to Week 284
Annual Change From Baseline Value From the Parent Phase 3 Studies in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) Score
時間枠:Up to Week 260

SDI score is used to assess the accumulated damage in participants with SLE. It assess 12 organ systems and records damage in participants with lupus, regardless of its cause. Damage could be due to previous disease activity, medication, or intercurrent illness (such as surgery or cancer). To distinguish between active inflammation and damage, an item must be present for at least 6 months. It is assumed that persistent inflammation (for at least 6 months) would result in tissue injury and hence damage. SDI is evaluated on a scale 0-47 with higher score indicating higher damage.

Up to Week 260
Cumulative Exposure to OCS Over Time
時間枠:Up to Week 260
Up to Week 260
Percentage of Participants With OCS ≤7.5 mg
時間枠:Up to Week 260
Up to Week 260
Percentage of Participants With OCS ≤5 mg
時間枠:Up to Week 260
Up to Week 260
Change From Baseline in Lupus-Specific Health-Related Quality-Of-Life (LupusQoL) Score
時間枠:Up to Week 260

The LupusQoL is a participant-reported, lupus-specific, HRQoL questionnaire consisting of 34 items grouped in 8 domains: physical health, pain, planning, intimate relationships, burden to others, emotional health, body image and fatigue. Participants indicate their responses on a 5-point Likert response format, where 4 = never, 3 = occasionally, 2 = a good bit of the time, 1 = most of the time, and 0 = all the time. A LupusQoL score for each domain will be reported on a 0 to 100 scale, with greater values indicating better HRQoL.

Up to Week 260
Change From Baseline in Short Form Health Survey-36 (SF-36) (Acute Version) Score
時間枠:Up to Week 156

The SF-36 is a 36-item scale which assesses HRQoL in 8 domains: limitations in physical activities due to health problems, limitations in social activities due to physical or emotional problems, limitations in usual role activities due to physical health problems, bodily pain, general mental health (psychological distress and well-being), limitations in usual role activities due to emotional problems, vitality (energy and fatigue), general health perceptions. The SF-36 (Acute Version) form asks for participants to reply to questions (items) according to how they have felt over a specifically defined period of time. Items 1-4 primarily contribute to the physical component summary (PCS) score of the SF-36. Items 5-8 primarily contribute to the mental component summary (MCS) score of the SF-36 where higher scores indicate best health. Scores on each item are summed and averaged (range: 0=worse health to 100=best possible health).

Up to Week 156
Change From Baseline in European Quality of Life 5 Dimensions 3 Level Version (EQ-5D-3L)
時間枠:Up to Week 156

The EQ-5D is a standardized generic measure of health status developed by the European Quality of Life Group. This study uses the EQ-5D-3L version of the instrument. This instrument consists of 2 sections. The first section comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. All dimensions are measured on a 3-point scale, 1: No problems; 2: Some problems; 3: Extreme problems. The second section comprises the Visual Analogue Scale, which records the respondent's self-rated health on a vertical scale ranging from 0 to 100, lower scores indicate the worst possible health state.

Up to Week 156
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score
時間枠:Up to Week 260

The FACIT-Fatigue is a participant-administered HRQoL questionnaire that evaluates participant's fatigue in 5 broad categories: physical well-being, social/family well-being, emotional well-being, functional well-being and additional concerns. The level of fatigue is measured by questions assessed on a 5-point scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The responses for each item are added to obtain a total score which ranges from 0 to 52, with a higher score indicating less fatigue.

Up to Week 260
Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Score
時間枠:Up to Week 260

The PHQ-9 is a participant-administered HRQoL questionnaire to screen for the presence and severity of depression. The PHQ-9 is a participant-reported outcome (PRO) that is used to measure depression in adults. It contains 9 questions, with a 2 week recall period. The PHQ-9 yields an overall severity score that can range from 0 to 27 with the following severity scores: 0-4 = none; 5-9 = mild; 10-14 = moderate; 15-19 = moderate-to-severe; and 20-27 = severe.

Up to Week 260
Change From Baseline in Work Productivity and Activity Impairment (WPAI):Lupus Score
時間枠:Up to Week 260

WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. Each score ranges from 0 to 100, with higher numbers indicating greater impairment and less productivity.

Up to Week 260
Change from Baseline in Patient Global Assessment (PtGA) Score
時間枠:Up to Week 260

The PtGA is participant-administered, single-item question evaluating the impact of health and illness, with responses ranging from very poor to very well on a 100 mm VAS. The participant will consider the previous week when addressing this question.

Up to Week 260
Number of Participants with Clinically Relevant Abnormalities in Standard Laboratory Parameters
時間枠:Up to Week 284

Standard laboratory parameters will include hematology, blood chemistry, urinalysis, and coagulation.

Up to Week 284
Number of Participants with Clinically Relevant Abnormalities in Electrocardiogram (ECG) Results
時間枠:Up to Week 260
Up to Week 260
Number of Participants with Antibodies to Litifilimab
時間枠:Up to Week 284
Up to Week 284

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Medical Director、Biogen

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年6月10日

一次修了 (推定)

2032年5月3日

研究の完了 (推定)

2032年5月3日

試験登録日

最初に提出

2022年4月25日

QC基準を満たした最初の提出物

2022年4月25日

最初の投稿 (実際)

2022年4月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年9月30日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 230LE306
  • 2021-006378-22 (EudraCT番号)
  • 2023-505635-13 (その他の識別子:EU CTIS Number)
  • 2023 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する